|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab plus pa-clitaxel versus bevacizumab plus capecitabine as first-linetreatment for HER2-negative metastatic breast cancer: in-terim efficacy results of the randomised, open-label,non-inferiority, phase 3 TURANDOT trial显示文摘 | Lang I Brodowicz T Ryvo L | 2013 | Lancet On-co/2013，14，2： | 1 |
| 2 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as irucst-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURAN- DOT trial显示文摘 | Lang I Brodowicz T Ryvo L | 2013 | Lancet Oncol2013，14，2： | 1 |
| 3 | A biochemotherapy regimen with concurrent administration of cisplatin,vinblastine,temozolomide (Temodal),interferon-alfa and interleukin-2 for metastatic melanoma:a phase Ⅱ study显示文摘 | Ron IG Sarid D Ryvo L | 2006 | Melanoma Res2006，16，1： | 1 |
| 4 | Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: A basis for tumor-promoting interactions显示文摘 | Gali Soria Neora Yaal-Hahoshen Elina Azenshtein Sima Shina Leonor Leider-Trejo Larisa Ryvo Efrat Cohen-Hillel Alex Shtabsky Marcelo Ehrlich Tsipi Meshel Iafa Keydar Adit Ben-Baruch | 2008 | Cytokine2008，，1： | 1 |
| 5 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer :interim efficacy results of the randomised, open- label,non-inferiority,phase 3 TURANDOT triM显示文摘 | Lang I Brodowicz T Ryvo L | 2013 | Lancet Onco12013，14，2： | 1 |
| 6 | Endocrine resis- tance in breast cancer:focus on the phosphatidylinositol 3- Kinase/Akt/Mammalian Target of Rapamycin signaling pathway显示文摘 | Hasson SP Rubinek T Ryvo L | 2013 | Breast Care (Basel)2013，8，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员